These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33217734)

  • 1. Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety.
    Allen WC; Greeson NM; Mixon W
    Int J Pharm Compd; 2020; 24(6):451-458. PubMed ID: 33217734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance.
    Greeson NM; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration.
    Greeson NMH; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(4):270-276. PubMed ID: 32649298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytic Methods Used in Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2017; 21(1):31-37. PubMed ID: 28346196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choosing a Vial Processing Line for Aseptic Compounding: Part 1.
    Noorian S; Vahedi N
    Int J Pharm Compd; 2016; 20(4):283-292. PubMed ID: 28333673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance Improvement in 503A Compounding Pharmacies: A PLAN FOR ASSESSMENT, IMPLEMENTATION, AND SUSTAINED SUCCESS.
    Pritchett J; Mixon W; O'Connell K
    Int J Pharm Compd; 2016; 20(1):29-36. PubMed ID: 27125054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ON SUPPLYING THE POPULATION WITH DRUGS].
    MAKSIMOVA TV; OLKHOVOI IV; TARASOVA LG
    Aptechn Delo; 1964; 13():54-7. PubMed ID: 14202553
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies.
    Pritchett J; McCrory G; Kraemer C; Jensen B; Allen LV
    Int J Pharm Compd; 2018; 22(1):7-16. PubMed ID: 29385381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2016; 20(6):481-484. PubMed ID: 28339387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relation of pharmaceutical to commercial drug preparations].
    Nord Med; 1953 Aug; 50(35):1202-3. PubMed ID: 13087833
    [No Abstract]   [Full Text] [Related]  

  • 16. Compounding practices in Iran.
    Goodarzi N; Niknam S; Akbarzadeh T; Gholami K
    Int J Pharm Compd; 2014; 18(2):112-6. PubMed ID: 24881113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving and enforcing compounding pharmacy practices to protect patients.
    Pegues DA
    Clin Infect Dis; 2006 Oct; 43(7):838-40. PubMed ID: 16941363
    [No Abstract]   [Full Text] [Related]  

  • 18. Leveraging a multidisciplinary oversight committee to ensure USP <797> and <800> compliance at a Veterans Affairs health system.
    Wrzesniewski CE; Park HK
    Am J Health Syst Pharm; 2022 Feb; 79(4):276-282. PubMed ID: 34724546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relation of pharmaceutical to commercial drug preparations in Denmark].
    Nord Med; 1953 Aug; 50(35):1203-4. PubMed ID: 13087834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.